0001493152-23-027375.txt : 20230809 0001493152-23-027375.hdr.sgml : 20230809 20230809164334 ACCESSION NUMBER: 0001493152-23-027375 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 33 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Galmed Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001595353 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981147233 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36345 FILM NUMBER: 231155879 BUSINESS ADDRESS: STREET 1: 16 ZE'EV TYOMKIN ST. (4TH FL.) CITY: TEL AVIV STATE: L3 ZIP: 6578317 BUSINESS PHONE: 97236938448 MAIL ADDRESS: STREET 1: 16 ZE'EV TYOMKIN ST. (4TH FL.) CITY: TEL AVIV STATE: L3 ZIP: 6578317 6-K 1 form6-k.htm
0001595353 false --12-31 Q2 2023 2023-06-30 0001595353 2023-01-01 2023-06-30 0001595353 2023-06-30 0001595353 2022-12-31 0001595353 2023-04-01 2023-06-30 0001595353 2022-04-01 2022-06-30 0001595353 2022-01-01 2022-06-30 0001595353 us-gaap:CommonStockMember 2022-12-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001595353 us-gaap:RetainedEarningsMember 2022-12-31 0001595353 us-gaap:CommonStockMember 2023-03-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001595353 us-gaap:RetainedEarningsMember 2023-03-31 0001595353 2023-03-31 0001595353 us-gaap:CommonStockMember 2021-12-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001595353 us-gaap:RetainedEarningsMember 2021-12-31 0001595353 2021-12-31 0001595353 us-gaap:CommonStockMember 2022-03-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001595353 us-gaap:RetainedEarningsMember 2022-03-31 0001595353 2022-03-31 0001595353 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001595353 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001595353 2023-01-01 2023-03-31 0001595353 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001595353 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001595353 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001595353 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001595353 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001595353 2022-01-01 2022-03-31 0001595353 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001595353 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001595353 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001595353 us-gaap:CommonStockMember 2023-06-30 0001595353 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001595353 us-gaap:RetainedEarningsMember 2023-06-30 0001595353 us-gaap:CommonStockMember 2022-06-30 0001595353 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001595353 us-gaap:RetainedEarningsMember 2022-06-30 0001595353 2022-06-30 0001595353 2023-07-01 2023-07-31 0001595353 GLMD:OnkaiIncMember 2023-06-30 0001595353 GLMD:OnkaiIncMember 2023-05-03 2023-05-04 0001595353 GLMD:OnkaiIncMember us-gaap:SubsequentEventMember 2023-11-29 2023-11-30 0001595353 GLMD:OnkaiIncMember 2023-01-01 2023-06-30 0001595353 GLMD:OnkaiIncMember 2023-06-18 2023-06-19 0001595353 GLMD:OnkaiIncMember 2023-06-19 0001595353 us-gaap:OperatingIncomeLossMember 2023-04-01 2023-06-30 0001595353 us-gaap:OperatingIncomeLossMember 2022-04-01 2022-06-30 0001595353 us-gaap:OperatingIncomeLossMember 2023-01-01 2023-06-30 0001595353 us-gaap:OperatingIncomeLossMember 2022-01-01 2022-06-30 0001595353 us-gaap:GainLossOnInvestmentsMember1 2023-04-01 2023-06-30 0001595353 us-gaap:GainLossOnInvestmentsMember1 2022-04-01 2022-06-30 0001595353 us-gaap:GainLossOnInvestmentsMember1 2023-01-01 2023-06-30 0001595353 us-gaap:GainLossOnInvestmentsMember1 2022-01-01 2022-06-30 0001595353 2023-06-29 2023-06-30 0001595353 2023-05-14 2023-05-15 0001595353 us-gaap:SubsequentEventMember 2023-07-17 2023-07-18 0001595353 us-gaap:SubsequentEventMember GLMD:PrefundedWarrantsMember us-gaap:WarrantMember 2023-07-18 0001595353 us-gaap:SubsequentEventMember GLMD:PrefundedWarrantsMember us-gaap:CommonStockMember 2023-07-18 0001595353 us-gaap:SubsequentEventMember us-gaap:WarrantMember GLMD:InvestorWarrantsMember 2023-07-18 0001595353 us-gaap:SubsequentEventMember us-gaap:CommonStockMember GLMD:InvestorWarrantsMember 2023-07-18 0001595353 us-gaap:SubsequentEventMember GLMD:InvestorWarrantsMember 2023-07-18 0001595353 us-gaap:SubsequentEventMember GLMD:PrefundedWarrantsMember 2023-07-18 0001595353 us-gaap:SubsequentEventMember GLMD:PrefundedWarrantsMember us-gaap:WarrantMember 2023-08-04 0001595353 us-gaap:SubsequentEventMember GLMD:PrefundedWarrantsMember us-gaap:CommonStockMember 2023-08-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS xbrli:shares utr:sqft GLMD:Integer iso4217:ILS

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of August 2023

 

001-36345

(Commission File Number)

 

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

 

16 Tiomkin St.

Tel Aviv 6578317, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

   

 

 

This Form 6-K contains the quarterly report of Galmed Pharmaceuticals Ltd. (the “Company”), which includes the Company’s unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2023, together with related information and certain other information. The Company is not subject to the requirements to file quarterly or certain other reports under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company does not undertake to file or cause to be filed any such reports in the future, except to the extent required by law.

 

This Form 6-K is incorporated by reference into the Company’s Registration Statement on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company’s Registration Statement on Form F-3 (Registration No. 333-254766).

 

   

 

 

FINANCIAL INFORMATION

 

Financial Statements

 

GALMED PHARMACEUTICALS LTD.

Interim Condensed Consolidated Balance Sheets (Unaudited)

U.S. Dollars in thousands, except share data and per share data

 

     As of   As of 
     June 30,   December 31, 
     2023   2022 
Assets            
             
Current assets            
Cash and cash equivalents    $1,009   $2,016 
Restricted Cash     115    114 
Marketable debt securities     7,556    11,769 
Short term Deposits     765    - 
Other receivables      341    825 
Total current assets     9,786    14,724 
             
Operating lease right-of-use assets     129    223 
Property and equipment, net     97    114 
Investment in SAFE notes     -    1,500 
Investment in associate at fair value3    3,265    - 
Total non-current assets     3,491    1,837 
             
Total assets    $13,277   $16,561 
             
Liabilities and stockholders’ equity            
             
Current liabilities            
Trade payables    $2,140   $2,560 
Other payables     583    534 
Total current liabilities     2,723    3,094 
             
Non-current liabilities            
Operating lease liabilities, net of current portion    $-   $44 
Total non-current liabilities     -    44 
             
Ordinary shares par value NIS 0.15 per share; Authorized 20,000,000; Issued and outstanding: 1,680,232 shares as of June 30, 2023 and as of December 31, 2022 (*)     70    70 
Additional paid-in capital     200,609    200,138 
Accumulated other comprehensive loss     (662)   (745)
Accumulated deficit     (189,463)   (186,040)
Total stockholders’ equity4   10,554    13,423 
             
Total liabilities and stockholders’ equity    $13,277   $16,561 

 

The accompanying notes are an integral part of the interim condensed   consolidated financial statements.  

 

(*) Retroactively adjusted (See Note 4.3)  

 

   

 

 

GALMED PHARMACEUTICALS LTD. 

Interim Condensed Consolidated Statements of Operations (Unaudited)

U.S. Dollars in thousands, except share data and per share data

 

                     
   Three months ended   Six months ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
Research and development expenses   809    2,580    1,892    7,376 
                     
General and administrative expenses   1,062    1,150    1,981    2,446 
                     
Total operating expenses   1,871    3,730    3,873    9,822 
                     
Financial expense (income), net   (278)   4    (450)   55 
                     
Net loss  $1,593   $3,734   $3,423   $9,877 
                     
Basic and diluted net loss per share  $0.95   $2.25(*)  $2.04   $5.85(*)
                     
Weighted-average number of shares outstanding used in computing basic and diluted net loss per share   1,680,232    1,672,561(*)   1,680,232    1,672,561(*)

 

(*) Retroactively adjusted (See Note 4.3)  

  

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

   

 

 

GALMED PHARMACEUTICALS LTD.

Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

U.S. Dollars in thousands

 

                     
   Three months ended   Six months ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
Net loss  $1,593   $3,734   $3,423   $9,877 
                     
Other comprehensive loss:                    
Net unrealized loss (gain) on available for sale securities   17    366    (83)   811 
                     
Comprehensive loss  $1,610   $4,100   $3,340   $10,688 

 

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

   

 

 

GALMED PHARMACEUTICALS LTD.

Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)

U.S. Dollars in thousands, except share data and per share data

 

                               
               Accumulated         
       Additional   other         
   Ordinary shares   paid-in   Comprehensive   Accumulated     
   Shares   Amount   capital   loss   Deficit   Total 
Balance – December 31, 2022   1,680,232(*)  $70   $200,138   $(745)  $(186,040)  $13,423 
Stock based compensation   -    -    297    -    -    297 
Unrealized gain from marketable debt securities   -    -    -    100    -    100 
Net loss                       (1,830)   (1,830)
Balance – March 31, 2023   1,680,232(*)  $70   $200,435   $(645)  $(187,870)  $11,990 
Stock-based compensation   -    -    174    -    -    174 
Unrealized loss from marketable debt securities   -    -    -    (17)   -    (17)
Net loss   -    -    -    -    (1,593)   (1,593)
Balance – June 30, 2023   1,680,232   $70   $200,609   $(662)  $(189,463)  $10,554 

 

               Accumulated         
       Additional   other         
   Ordinary shares   paid-in   Comprehensive   Accumulated     
   Shares (*)   Amount   capital   loss   Deficit   Total 
Balance – December 31, 2021    1,672,561   $70   $198,772   $(171)  $(168,174)  $30,497 
Stock based compensation   -    -    457    -    -    457 
Unrealized loss from marketable debt securities   -    -    -    (445)   -    (445)
Net loss                       (6,143)   (6,143)
Balance – March 31, 2022   1,672,561   $70   $199,229   $(616)  $(174,317)  $24,366 
Stock-based compensation   -    -    446    -    -    446 
Unrealized loss from marketable debt securities   -    -    -    (366)   -    (366)
Net loss   -    -    -    -    (3,734)   (3,734)
Balance – June 30, 2022   1,672,561   $70   $199,675   $(982)  $(178,051)  $20,712 

 

(*)Retroactively adjusted (See Note 4.3).

 

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

   

 

 

GALMED PHARMACEUTICALS LTD.

 Interim Condensed Consolidated Statements of Cash Flows (Unaudited) 

U.S. Dollars in thousands

 

           
   Six months ended 
   June 30, 
   2023   2022 
Cash flow from operating activities          
           
Net loss  $(3,423)  $(9,877)
           
Adjustments required to reconcile net loss to net cash used in operating activities          
Depreciation and amortization   17    18 
Stock-based compensation expense   471    903 
Amortization of premium on marketable debt securities   15    35 
Change in fair value of SAFE investment   (265)   - 
Interest income from short-term deposits   (16)   - 
Gain from realization of marketable debt securities   (25)   201 
Finance expenses   (2)   (42)
Changes in operating assets and liabilities:          
Decrease in other accounts receivable   484    511 
Decrease in trade payables   (420)   (2,782)
Increase (decrease) in other accounts payable   102    (330)
Net cash used in operating activities   (3,062)   (11,363)
           
Cash flow from investing activities          
Purchase of property and equipment   -    (3)
Purchase of available for sale securities   (3,218)   10,462 
Investment in equity of Onkai   (1,500)   - 
Investment in short term deposits   (750)   - 
Sale of available-for-sale securities   7,524    - 
Net cash provided by (used in) investing activities   2,056    10,459 
           
Decrease in cash and cash equivalents and restricted cash   (1,006)   (904)
Cash and cash equivalents and restricted cash at the beginning of the period   2,130    2,998 
Cash and cash equivalents and restricted cash at the end of the period  $1,124   $2,094 
           
Supplemental disclosure of cash flow information:          
           
Cash received from interest  $163   $138 
           
Non-cash investment transaction:          
Conversion of SAFE into equity of OnKai  $1,765    - 

 

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

   

 

 

GALMED PHARMACEUTICALS LTD.

Notes to Interim Condensed Consolidated Financial Statements

 

Note 1 - Basis of presentation

 

Galmed Pharmaceuticals Ltd. (the “Company”) was incorporated in Israel on July 31, 2013 and commenced operations on February 2, 2014.

 

The Company holds a wholly-owned subsidiary, Galmed International Ltd., which was incorporated in Malta.

 

The Company also holds two additional wholly-owned subsidiaries, Galmed Research and Development Ltd and Galtopa Therapeutics Ltd., both of which are incorporated in Israel.  In July 2023 Galmed Research and Development Ltd established a new wholly-owned subsidiary incorporated under the laws of England and Wales called Galmed Therapeutics  UK limited.

 

The Company is a clinical stage biopharmaceutical company primarily focused on the development of its product candidate Aramchol for liver and fibro-inflammatory diseases. The Company has focused almost exclusively on developing Aramchol for the treatment of NASH and is currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease. The Company is also collaborating with the Hebrew University in the development of Amilo-5MER. The Company has an operating history limited to pre-clinical and clinical drug development.

 

In May 2023, the Company announced the initiation of a new clinical program to evaluate Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC).

 

In addition, in May 2023, the Company entered into a definitive agreement with OnKai, Inc. (“Onkai”) for an equity investment in Onkai. See note 3.

 

The Company funded its research and development programs and operations to date primarily through proceeds from private placements and public offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date. As of June 30, 2023, the Company had cash and cash equivalents of $1.0 million, short term deposit of $0.8 million, restricted cash of $0.1 million, and marketable debt securities of $7.6 million. In July 2023, the Company completed a public offering resulting in net proceeds of approximately $6.2 million.

 

The Company has incurred operating losses in each year since inception. The Company’s loss attributable to holders of its ordinary shares for the six months period ended June 30, 2023, was approximately $3.4 million. As of June 30, 2023, the Company had an accumulated deficit of $189.5 million. Substantially all of its operating losses resulted from costs incurred in connection with the Company’s development program and from general and administrative costs associated with its operations. 

 

The Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol for, and beyond its current development stage and any future commercialization, as well as any additional indications.

 

Based on the Company’s current operating plan, the Company’s management currently estimates that its cash position will support its current clinical trials and operations as currently conducted for more than 12 months from the date of issuance of these financial statements.

 

These unaudited interim condensed consolidated financial statements have been prepared as of June 30, 2023, and for the three and six month period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2022 that are included in the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 29, 2023 (the “Annual Report on Form 20-F”). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2023.

 

   

 

 

GALMED PHARMACEUTICALS LTD.

Notes to Interim Condensed Consolidated Financial Statements

 

 

Note 2 - Summary of significant accounting policies  

 

The significant accounting policies that have been applied in the preparation of the unaudited consolidated interim financial statements are identical to those that were applied in preparation of the Company’s most recent annual financial statements in connection with its Annual Report on Form 20-F, other than:

 

Investment in Equity Securities

 

The Company entered into an investment in which it holds approximately 24% of the outstanding shares and voting rights of Onkai. The Company has elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management believes this approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured at fair value (level 3) at each reporting period through earnings

 

Note 3 – Investment in Associate at Fair Value

 

On May 4, 2023, the Company entered into a definitive agreement (the “Agreement”) for a $1.5 million equity investment in OnKai, a US-based technology company developing an AI-based platform to advance healthcare for underserved populations across the United States by facilitating alignment between healthcare stakeholders.

 

Previously, on November, 2023 the Company invested $1.5 million in OnKai through a Simple Agreement for Future Equity which converted at a 15% discount into series seed preferred shares upon closing of the Investment Round.

 

The Company’s investment in OnKai was part of an approximately $6 million investment round (the “Investment Round”) with other investors that was led by the Company of which SAFE notes of approximately $3.8 million were converted into preferred shares. On June 19, 2023, the Investment Round closed. Following the closing of the Investment Round, the Company holds 1,223,535 preferred shares which comprises approximately 23.9% of the outstanding share capital of OnKai on an as-converted basis. and the Company’s Chief Executive Officer and director, Allen Baharaff serves as a board member of OnKai.  

 

Under the terms of the Agreement, during the three-year period following the closing of the Investment Round the Company will have the right to merge with OnKai subject to the approval of the boards of directors of each of the Company and OnKai. The Company is granted certain customary pre-emptive rights as well as registration rights, first refusal rights, co-sale rights and broad based weighted average anti-dilution rights, a board seat, and certain customary protective provisions.

 

In connection with the Agreement, the Company’s wholly-owned subsidiary, Galmed Research and Development Ltd. (“GRD”), entered into a services agreement with OnKai. The Services Agreement provides that GRD will on a non-exclusive basis (i) provide support services to OnKai relating to finance, business development, strategic planning, execution and others; and (ii) lend its experience to OnKai in building a strategy and for the development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan preparation to serve GRD’s vision of developing drugs for the underserved population and (ii) when relevant, design a process on the clinical trial dashboard that could potentially serve GDR’s future trial.  

 

Summarized statement of operations (in thousands):

 

                     
   Three months ended   Six months ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
                 
Total operating loss  $573  

$

286   $1,171  

$

536 
                     
Net loss  $769   $349   $1,584   $648 

 

   

 

 

GALMED PHARMACEUTICALS LTD.

Notes to Interim Condensed Consolidated Financial Statements

 

Note 4 - Stockholders’ Equity

 

1.On March 23, 2023, the Company received a ruling from the Israel Tax Authority (“ITA”) confirming the repricing of stock options. This repricing was accounted for as a modification of a share-based payment award. The incremental compensation expense recognized as a result of the modification during the period ended June 30, 2023 was approximately $0.1 million.

 

2.On May 15, 2023 the Company effected a reverse share split of the Company’s ordinary shares at the ratio of 1-for-15, such that each fifteen (15) ordinary shares, par value NIS 0.01 per share, shall be consolidated into one (1) ordinary share, par value NIS 0.15. As a result, all share and per share amounts were adjusted retroactively for all periods presented in these financial statements.

 

3.In July 2023, we completed a public offering resulting in net proceeds of approximately $6.2 million. See note 5 for further details.

 

Note 5 – Subsequent Events

 

On July 18, 2023, the Company sold to investors in a public offering (i) 380,000 ordinary shares, (ii) 5,220,000 pre-funded warrants to purchase 5,220,000 ordinary shares (the “Pre-Funded Warrants”), and (iii) 5,600,000 warrants to purchase 5,600,000 ordinary shares (the “Investor Warrants”), at a purchase price of $1.25 per Share and accompanying Investor Warrant and $1.249 per Pre-Funded Warrant and accompanying Investor Warrant.  

 

The Pre-Funded Warrants are immediately exercisable at an exercise price of $0.001 per ordinary share and will not expire until exercised in full. The Investor Warrants have an exercise price of $1.25 per ordinary share, are immediately exercisable, and may be exercised until July 18, 2028. The net proceeds to the Company, were approximately $6.2 million.

 

As of August 4, 2023, a total of 2,121,041 Pre-Funded Warrants were exercised into 2,121,041 ordinary shares.

 

   

 

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

All references to “we,” “us,” “our,” “the Company” and “our Company”, in this Form 6-K are to Galmed Pharmaceuticals Ltd. and its subsidiaries, unless the context otherwise requires. All references to “shares” or “ordinary shares” are to our ordinary shares, NIS 0.15 nominal par value per share. All references to “Israel” are to the State of Israel. “U.S. GAAP” means the generally accepted accounting principles of the United States. Unless otherwise stated, all of our financial information presented in this Form 6-K has been prepared in accordance with U.S. GAAP. Any discrepancies in any table between totals and sums of the amounts and percentages listed are due to rounding. Unless otherwise indicated, or the context otherwise requires, references in this Form 6-K to financial and operational data for a particular year refer to the fiscal year of our company ended December 31 of that year.

 

Our reporting currency and financial currency is the U.S. dollar. In this Form 6-K, “NIS” means New Israeli Shekel, and “$,” “US$” and “U.S. dollars” mean United States dollars.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Form 6-K contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should,” “anticipate,” “could,” “might,” “seek,” “target,” “will,” “project,” “forecast,” “continue” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements may be included in, among other things, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below:

 

●   the timing and cost of our pivotal Phase 3 ARMOR trial, or the ARMOR Study, for our product candidate, Aramchol, or for any other pre-clinical or clinical trials;
     
●   completion and receiving favorable results of the ARMOR Study for Aramchol or any other pre-clinical or clinical trial;
     
●   regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling;
     
●   the commercial launch and future sales of Aramchol and any future product candidates;
     
●   our ability to comply with all applicable post-market regulatory requirements for Aramchol or any other product candidate in the countries in which we seek to market the product;
     
●   our ability to achieve favorable pricing for Aramchol or any other product candidate;
     
●   our expectations regarding the commercial market for non-alcoholic steato-hepatitis, or NASH, in patients or any other targeted indication;
     
●   third-party payor reimbursement for Aramchol or any other product candidate;
     
●   our estimates regarding anticipated capital requirements and our needs for additional financing;
     
●   market adoption of Aramchol or any other product candidate by physicians and patients;
     
●   the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate;
     
●   our ability to obtain and maintain adequate protection of our intellectual property;
     
●   the possibility that we may face third-party claims of intellectual property infringement;
     
●   our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost;
     
●   our ability to establish adequate sales, marketing and distribution channels;
     
●   intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;
     
●   the development and approval of the use of Aramchol or any other product candidate for additional indications or in combination therapy;
     
●   our expectations regarding licensing, acquisitions and strategic operations;
     
●   current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and
     
●   our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market.

 

   

 

 

We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2022, filed with the SEC on March 29, 2023 in greater detail under the heading “Risk Factors” and elsewhere in the Annual Report and this Form 6-K. Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events.

 

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

 

Overview

 

We are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for the treatment of liver disease and are currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.

 

In September 2019, we initiated our Phase 3 ARMOR Study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. The ARMOR Study was originally comprised of two parts, a randomized, double-blind, placebo-controlled histology-based registrational part and a clinically based part where subjects will continue with the same treatment for approximately five years. In December 2020, we announced the addition of a 150-patient open label part to the ARMOR Study and suspended randomization of new patients into the double-blind, placebo-controlled histology-based registrational part of ARMOR as all enrolled patients were transitioned to the open label part.

 

In May 2022, we announced our plan to expand into new anti-fibrotic indications to maximize the potential of Aramchol while at the same time discontinuing the open label part of its ARMOR Study having reached its objectives. Simultaneously, we initiated a cost reduction plan and initiated a process to evaluate our strategic alternatives. Following the discontinuation of our open label part of the ARMOR Study, we do not currently expect to initiate the second part of the ARMOR Study in the near term.

 

In May 2023, we announced the initiation of a new clinical program to evaluate Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC), a rare disease for which there is no approved treatment. We plan to initiate a Phase 2 study in the last quarter of 2023. The single-arm, open label, proof-of-concept clinical trial will evaluate the effects of 24 weeks of treatment with Aramchol meglumine in approximately 15 patients with PSC. The study’s endpoints will include the conventional relevant laboratory parameters (alkaline phosphatase and bilirubin), sophisticated imaging including liver stiffness using MR Elastography (MRE), imaging of the biliary tract using MR cholangiopancreatography (MRCP) and hepatocyte-specific contrast agents, histological fibrosis and molecular assessment as well as a range of biomarkers of disease activity and fibrosis. These endpoints are expected to provide a robust assessment of the underlying disease and the effects of Aramchol.

 

In addition, in May 2023, we entered into a definitive agreement (the “Agreement”) for a $1.5 million equity investment in OnKai Inc. (“OnKai”), a US-based technology company developing an AI-based platform to advance healthcare for underserved populations across the United States by facilitating alignment between healthcare stakeholders. The signing of the definitive agreement followed an announcement that we made in January 2023 that we had entered into a non-binding termsheet for an equity investment in OnKai. The Agreement provided that we will invest $1.5 million in exchange for series seed preferred shares of OnKai (which is in addition to a $1.5 million investment that was made by the Company in OnKai through a Simple Agreement for Future Equity and which converted at a 15% discount into series seed preferred shares upon consummation of the Investment Round (as defined below)). The Company’s investment in OnKai was part of an approximately $6 million investment round (the “Investment Round”) with other investors that was led by the Company of which SAFE notes of approximately $3.8 million were converted into preferred shares. On June 19, 2023, the Investment Round closed. Following the Investment Round, we hold approximately 23.9% of the outstanding share capital of OnKai on an as-converted and fully and our Chief Executive Officer and director, Allen Baharaff serves as a board member of OnKai. In connection with the Agreement, the our wholly-owned subsidiary, Galmed Research and Development Ltd. (“GRD”), entered into a services agreement (the “Services Agreement”) with OnKai. The Services Agreement provides that GRD shall on a non-exclusive basis (i) provide support services to OnKai relating to finance, business development, strategic planning, execution and others; and (ii) lend its experience to OnKai in building a strategy and for the development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan preparation to serve GDR’s vision of developing drugs for the underserved population and (ii) when relevant, design a process on the clinical trial dashboard that could potentially serve GDR’s future trial.

 

In view of our initiation of our PSC clinical program and our investment and collaboration with Onkai, we are no longer evaluating our strategic alternatives.

 

Financial Overview

 

To date, we have funded our operations primarily through proceeds from private placements and public offerings. At June 30, 2023, we had current assets of $9.8 million, which includes cash and cash equivalents of $1.0 million, marketable debt securities of $7.5 million, other receivables of $0.3 million and restricted cash of $0.1 million. This compares with current assets of $14.7 million at December 31, 2022, which includes cash and cash equivalents of $2 million, marketable debt securities of $11.8 million, other receivables if $0.8 million and restricted cash of $0.1 million. In July 2023, we completed a public offering resulting in net proceeds of approximately $6.2 million.

 

Although we provide no assurance, we believe that such existing funds will be sufficient to continue our business and operations as currently conducted for more than 12 months from the date of issuance of this Form 6-K. However, we will continue to incur operating losses, which may be substantial over the next several years, and we expect that we will need to obtain additional funds to further develop our research and development programs.

 

   

 

 

Costs and Operating Expenses

 

Our current costs and operating expenses consist of two components: (i) research and development expenses; and (ii) general and administrative expenses.

 

Research and Development Expenses

 

Our research and development expenses consist primarily of outsourced development expenses, salaries and related personnel expenses and fees paid to external service providers, patent-related legal fees, costs of pre-clinical studies and clinical trials and drug and laboratory supplies. We account for all research and development expenses as they are incurred. We expect our research and development expense to remain our primary expense in the near future as we continue to develop Aramchol. Increases or decreases in research and development expenditures are primarily attributable to the number and/or duration of the pre-clinical and clinical studies that we conduct.

 

We expect that a substantial amount of our research and development expense in the future will be incurred in support of our current and anticipated pre-clinical and clinical development projects. Due to the inherently unpredictable nature of pre-clinical and clinical development studies and unpredictability of our evaluation of strategic alternatives, we are unable to estimate with any certainty the costs we will incur in the continued development of Aramchol for NASH and other indications in our pipeline for potential partnering and/or commercialization. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We currently expect to continue testing Aramchol in pre-clinical studies for toxicology, safety and efficacy, and to conduct additional clinical trials for Aramchol. Nevertheless, we expect to decrease our research and development expenses as a result of the discontinuation of the Open Label Part of the ARMOR Study and our evaluation of strategic alternatives.

 

The lengthy process of completing clinical trials and seeking regulatory approval for Aramchol requires the expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of compensation for employees in executive and operational roles, including finance/accounting, legal and other operating positions in connection with our activities. Our other significant general and administrative expenses include non-cash stock-based compensation costs and facilities costs (including the rental expense for our offices in Tel Aviv, Israel), professional fees for outside accounting and legal services, travel costs, investors relations, insurance premiums and depreciation.

 

We anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, increased legal and accounting costs and investor relations costs. Our general and administrative expenses may also increase due to increases in professional and advisory fees as we evaluate our strategic alternatives.

 

Financial Income, Net

 

Our financial income, net consists mainly of interest income from marketable debt securities, Change in fair value of convertible note and foreign currency gains. Our financial expense consists of fees associated with banking activities and losses from realization of marketable debt securities.

 

   

 

 

Results of Operations

 

The table below provides our results of operations for the three and six months ended June 30, 2023, as compared to the three and six months ended June 30, 2022.

 

   Three months ended June 30,   Six months ended June 30, 
   2023   2022   2023   2022 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
   (In thousands, except per share data) 
Research and development expenses   809    2,580    1,892    7,376 
General and administrative expenses   1,062    1,150    1,981    2,446 
Total operating expenses   1,871    3,730    3,873    9,822 
Financial income, net   (278)   4    (450)   55 
Net loss   1,593    3,734    3,423    9,877 
Other comprehensive loss:   17    366    (83)   811 
Comprehensive loss   1,610    4,100    3,340    10,688 
Basic and diluted net loss per share  $0.95   $2.25   $2.04   $5.85 

 

Research and Development Expenses

 

Our research and development expenses amounted to approximately $0.8 million and approximately $1.9 million during the three and six months ended June 30, 2023, respectively, representing a decrease of approximately $1.8 million, or 69%, and approximately $5.5 million, or 74%, respectively, compared to approximately $2.6 million and approximately $7.4 million, respectively, for the comparable period in 2022.

 

The decrease during the three months ended June 30, 2023, primarily resulted mainly from a decrease in chemistry and formulation studies of approximately $0.9 million and decrease in salaries and benefits of approximately $0.3 million. The decrease during the six months ended June 30, 2023, primarily resulted from a decrease in clinical trial expenses of approximately $2.3 million and chemistry and formulation studies of approximately $1.4 million.

 

General and Administrative Expenses

 

Our general and administrative expenses amounted to approximately $1.1 million and approximately $2.0 million during the three and six months ended June 30, 2023, respectively, representing a decrease of approximately $0.1 million, or 8%, and approximately $0.4 million, or 17%, respectively, to approximately $1.2 million and approximately $2.4 million, respectively, for the comparable period in 2022.

 

The decrease in general and administrative expenses for the three and six months ended June 30, 2023, resulted primarily from a decrease in stock-based compensation expense of $0.2 million and $0.3 million, respectively.

 

Operating Loss

 

As a result of the foregoing, for the three and six months ended June 30, 2023, our operating loss was approximately $1.9 million and approximately $3.9 million, respectively, representing a decrease of $1.8 million, or 49%, and a decrease of $5.9 million, or 60%, respectively, as compared to approximately $3.7 million and approximately $9.8 million, respectively, for the comparable period in 2022.

 

Financial Income, Net

 

Our financial income, net amounted to approximately $0.3 million and approximately $0.5 million during the three and six months ended June 30, 2023, respectively, representing an increase of approximately $0.3 million, and approximately $0.5 million, respectively, compared to financial expense, net of less than $0.1 million and $0.1 million, respectively, for the comparable period in 2022. The Increase in financial income, net for the three and six months ended June 30, 2023, resulted primarily from income from Change in fair value of convertible SAFE note.

 

Net Loss

 

As a result of the foregoing, for the three and six months ended June 30, 2023, our net loss was approximately $1.6 million and approximately $3.4 million, respectively, representing a decrease of $2.1 million, or 57%, and a decrease of $6.5 million, or 66%, respectively, as compared to approximately $3.7 million and approximately $9.9 million, respectively, for the comparable period in 2022.

 

   

 

 

Liquidity and Capital Resources

 

To date, we have funded our operations primarily through proceeds from private placements and public offerings and we have incurred substantial losses since our inception. As of June 30, 2023, we had an accumulated deficit of approximately $189.5 million and positive working capital (current assets less current liabilities) of approximately $7.1 million. We expect that operating losses will continue for the foreseeable future.

 

As of June 30, 2023, we had cash and cash equivalents of approximately $1.0 million, short term deposit of $0.8 million, restricted cash of approximately $0.1 million, and marketable debt securities of approximately $7.6 million invested in accordance with our investment policy, totaling approximately $9.4 million, as compared to approximately $2.0 million, $0, $0.1 million and $11.8 million as of December 31, 2022, respectively, totaling approximately $13.9 million. The decrease is mainly attributable to the $3.1 million negative cash flow from operating activities during the six months ended June 30, 2023. In July 2023, we completed a public offering resulting in net proceeds of approximately $6.2 million.

 

We had negative cash flow from operating activities of approximately $3.1 million for the six months ended June 30, 2023, as compared to negative cash flow from operating activities of approximately $11.3 million for the six months ended June 30, 2022. The negative cash flow from operating activities for the six months ended June 30, 2023, is mainly attributable to our net loss of approximately $3.4 million.

 

We had positive cash flow from investing activities of approximately $2.1 million for the six months ended June 30, 2023, as compared to a positive cash flow from investing activities of approximately $10.5 million for the six months ended June 30, 2022. The positive cash flow from investing activities for the six months ended June 30, 2023, was primarily due to net withdrawal of approximately $4.3 million from available for sale securities, partially offset by investment in an associate of $1.5 million.

 

We had no cash flow from financing activities for the six months ended June 30, 2023.

 

On March 26, 2021, we entered into a Sales Agreement with Cantor Fitzgerald & Co. and Canaccord Genuity LLC, as sales agents, pursuant to which we may offer and sell ordinary shares “at the market” having an aggregate offering price of up to $50.0 million from time to time through the sales agents subject to the limits of General Instruction I.B.5 to Form F-3, also known as the baby shelf rule. As of June 30, 2023, we sold 7,666 ordinary shares under our ATM program for total net proceeds of approximately $0.1 million.

 

Although we provide no assurance, we believe that our existing funds will be sufficient to continue our business and operations as currently conducted for more than 12 months from the date of issuance of this Report on Form 6-K. However, additional funding will be necessary to fund our ARMOR Study, our Amilo-5MER program and ongoing research and development work, to advance our product candidates through regulatory approval and into commercialization, if approved and the evaluation of our strategic alternatives. We intend to obtain additional funding through debt or equity financings, governmental grants or through entering into collaborations, strategic alliances or license agreements to increase the funds available to support our operating and capital needs. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining additional financing on terms acceptable to us. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to Aramchol, Amilo-5MER and/or our other pre-clinical and clinical programs. This may raise substantial doubts about our ability to continue as a going concern.

 

   

 

 

The extent of our future capital requirements will depend on many other factors, including:

 

  ● the progress and costs of our pre-clinical studies, clinical trials and other research and development activities;
     
  ● the regulatory pathway of Aramchol, Amilo-5MER or any other product candidate;
     
  ● the scope, prioritization and number of our clinical trials and other research and development programs;
     
  ● the amount of revenues and contributions we receive under future licensing, development and commercialization arrangements with respect to Aramchol or any other product candidtate;
     
  ● the costs of the development and expansion of our operational infrastructure;
     
  ● the costs and timing of obtaining regulatory approval for Aramchol, Amilo-5MER or any other product candidate;
     
  ● the ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under our potential future licensing agreements;
     

  ● the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
     
  ● the costs and timing of securing manufacturing arrangements for clinical or commercial production;
     
  ● the costs of contracting with third parties to provide sales and marketing capabilities for us;
     
  ● the costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or platforms;
     
  ● the magnitude of our general and administrative expenses;
     
  ● any cost that we may incur under future in- and out-licensing arrangements relating to Aramchol, Amilo-5MER or any other product candidate;
     
  ● market conditions;
     
  ● our ability to identify, evaluate and complete any strategic alternative that yields value for our shareholders; and
     
  ● the impact of any resurgence of the COVID-19 pandemic and the Russian invasion of Ukraine, which may exacerbate the magnitude of the factors discussed above.

 

Trend Information

 

We are a development stage company, and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization efforts. As such, it is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would cause financial information to not necessarily be indicative of future operating results or financial condition. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

 

Controls and Procedures

 

As a “foreign private issuer”, we are only required to conduct the evaluations required by Rules 13a-15(b) and 13a-15(d) of the Exchange Act as of the end of each fiscal year and therefore have elected not to provide disclosure regarding such evaluations at this time.

 

Reverse Split

 

On May 12, 2023, we effected a reverse share split of our ordinary shares at the ratio of 1-for-15, such that each fifteen (15) ordinary shares, par value NIS 0.01 per share, were consolidated into one (1) ordinary share, par value NIS 0.15. May 15 2023 was the first date when our ordinary shares began trading on the Nasdaq Stock Market LLC after implementation of the reverse split.

 

   

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Galmed Pharmaceuticals Ltd.
     
Date: August 9, 2023 By: /s/ Allen Baharaff
    Allen Baharaff
    President and Chief Executive Officer

 

   

 EX-101.SCH 2 glmd-20230630.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Interim Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Changes In Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis of presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Investment in Associate at Fair Value link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Investment in Associate at Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Basis of presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of significant accounting policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Statement of operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Investment in Associate at Fair Value (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 glmd-20230630_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 4 glmd-20230630_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 glmd-20230630_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Investment, Name [Axis] Onkai Inc [Member] Title of Individual [Axis] Subsequent Event Type [Axis] Subsequent Event [Member] Income Statement Location [Axis] Operating Income (Loss) [Member] Gain (Loss) on Investments [Member] Sale of Stock [Axis] Prefunded Warrants [Member] Warrant [Member] Investor Warrants [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Restricted Cash Marketable debt securities Short term Deposits Other receivables Total current assets Operating lease right-of-use assets Property and equipment, net Investment in SAFE notes Investment in associate at fair value Total non-current assets Total assets Liabilities and stockholders’ equity Current liabilities Trade payables Other payables Total current liabilities Non-current liabilities Operating lease liabilities, net of current portion Total non-current liabilities Ordinary shares par value NIS 0.15 per share; Authorized 20,000,000; Issued and outstanding: 1,680,232 shares as of June 30, 2023 and as of December 31, 2022 () Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Outstanding Income Statement [Abstract] Research and development expenses General and administrative expenses Total operating expenses Financial expense (income), net Net loss Net loss per share, diluted Net loss per share, basic Weighted average number of shares outstanding used in computing net loss per share, basic Weighted average number of shares outstanding used in computing net loss per share, diluted Net loss Other comprehensive loss: Net unrealized loss (gain) on available for sale securities Comprehensive loss Statement [Table] Statement [Line Items] Balance Balance, shares Stock-based compensation Unrealized loss from marketable debt securities Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flow from operating activities Adjustments required to reconcile net loss to net cash used in operating activities Depreciation and amortization Stock-based compensation expense Amortization of premium on marketable debt securities Change in fair value of SAFE investment Interest income from short-term deposits Gain from realization of marketable debt securities Finance expenses Changes in operating assets and liabilities: Decrease in other accounts receivable Decrease in trade payables Increase (decrease) in other accounts payable Net cash used in operating activities Cash flow from investing activities Purchase of property and equipment Purchase of available for sale securities Investment in equity of Onkai Investment in short term deposits Sale of available-for-sale securities Net cash provided by (used in) investing activities Decrease in cash and cash equivalents and restricted cash Cash and cash equivalents and restricted cash at the beginning of the period Cash and cash equivalents and restricted cash at the end of the period Supplemental disclosure of cash flow information: Cash received from interest Non-cash investment transaction: Conversion of SAFE into equity of OnKai Accounting Policies [Abstract] Basis of presentation Summary of significant accounting policies Investments, All Other Investments [Abstract] Investment in Associate at Fair Value Equity [Abstract] Stockholders’ Equity Subsequent Events [Abstract] Subsequent Events Investment in Equity Securities Summary of Statement of operations Date Of Incorporation Operations Commenced Date Short-term deposits Restricted cash Marketable securities debt Proceeds from issuance of initial public offering Profit loss Retained earnings accumulated deficit Equity Method Investment, Ownership Percentage Total operating loss Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Value conversion Capital stock discount rate Investment Stock Issued During Period, Shares, Other Converted basis Subsequent Event [Table] Subsequent Event [Line Items] Other Expenses Stockholders' Equity Note, Stock Split Number of ordinary shares Stock and warrants issued during period shares Stock and warrants issued during period shares Shares issued price per share Shares issued price per share Finance expenses amount. Change in fair value of investment. Conversion of safe into equity of onkai. Onkai Inc [Member] Capital stock discount rate. Prefunded Warrants [Member] Investor Warrants [Member] Summary of Statement of Operations [Table Text Block] Assets, Current Assets, Noncurrent Assets [Default Label] Liabilities, Current Liabilities, Noncurrent Equity, Attributable to Parent Liabilities and Equity Operating Expenses Other Nonoperating Income (Expense) Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Interest Income, Short-Term Investment, Other Marketable Securities, Gain (Loss) Increase (Decrease) in Accounts and Other Receivables Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments for (Proceeds from) Available-for-Sale Securities, Short-Term Payments to Acquire Equity Method Investments Payments for (Proceeds from) Short-Term Investments Net Cash Provided by (Used in) Investing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Class of Warrant or Right, Number of Securities Called by Warrants or Rights Shares Issued, Price Per Share EX-101.PRE 6 glmd-20230630_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
 6 Months Ended
Jun. 30, 2023
Cover [Abstract]  
Document Type 6-K
Amendment Flag false
Document Period End Date Jun. 30, 2023
Document Fiscal Period Focus Q2
Document Fiscal Year Focus 2023
Current Fiscal Year End Date --12-31
Entity File Number 001-36345
Entity Registrant Name GALMED PHARMACEUTICALS LTD.
Entity Central Index Key 0001595353
Entity Address, Address Line One 16 Tiomkin St.
Entity Address, City or Town Tel Aviv
Entity Address, Country IL
Entity Address, Postal Zip Code 6578317
XML 8 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Interim Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 1,009 $ 2,016
Restricted Cash 115 114
Marketable debt securities 7,556 11,769
Short term Deposits 765
Other receivables 341 825
Total current assets 9,786 14,724
Operating lease right-of-use assets 129 223
Property and equipment, net 97 114
Investment in SAFE notes 1,500
Investment in associate at fair value 3,265
Total non-current assets 3,491 1,837
Total assets 13,277 16,561
Current liabilities    
Trade payables 2,140 2,560
Other payables 583 534
Total current liabilities 2,723 3,094
Non-current liabilities    
Operating lease liabilities, net of current portion 44
Total non-current liabilities 44
Ordinary shares par value NIS 0.15 per share; Authorized 20,000,000; Issued and outstanding: 1,680,232 shares as of June 30, 2023 and as of December 31, 2022 () [1] 70 70
Additional paid-in capital 200,609 200,138
Accumulated other comprehensive loss (662) (745)
Accumulated deficit (189,463) (186,040)
Total stockholders’ equity 10,554 13,423
Total liabilities and stockholders’ equity $ 13,277 $ 16,561
[1] Retroactively adjusted (See Note 4.3)  
XML 9 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Dec. 31, 2022
₪ / shares
shares
Statement of Financial Position [Abstract]  
Common Stock, Par or Stated Value Per Share | ₪ / shares ₪ 0.15
Common Stock, Shares Authorized 20,000,000
Common Stock, Shares, Outstanding 1,680,232
XML 10 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Research and development expenses $ 809 $ 2,580 $ 1,892 $ 7,376
General and administrative expenses 1,062 1,150 1,981 2,446
Total operating expenses 1,871 3,730 3,873 9,822
Financial expense (income), net (278) 4 (450) 55
Net loss $ 1,593 $ 3,734 $ 3,423 $ 9,877
Net loss per share, diluted $ 0.95 $ 2.25 [1] $ 2.04 $ 5.85 [1]
Net loss per share, basic $ 0.95 $ 2.25 [1] $ 2.04 $ 5.85 [1]
Weighted average number of shares outstanding used in computing net loss per share, basic 1,680,232 1,672,561 [1] 1,680,232 1,672,561 [1]
Weighted average number of shares outstanding used in computing net loss per share, diluted 1,680,232 1,672,561 [1] 1,680,232 1,672,561 [1]
[1] Retroactively adjusted (See Note 4.3)  
XML 11 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Net loss $ 1,593 $ 3,734 $ 3,423 $ 9,877
Other comprehensive loss:        
Net unrealized loss (gain) on available for sale securities 17 366 (83) 811
Comprehensive loss $ 1,610 $ 4,100 $ 3,340 $ 10,688
XML 12 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Changes In Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 70 $ 198,772 $ (171) $ (168,174) $ 30,497
Balance, shares at Dec. 31, 2021 [1] 1,672,561        
Stock-based compensation 457 457
Unrealized loss from marketable debt securities (445) (445)
Net loss       (6,143) (6,143)
Balance at Mar. 31, 2022 $ 70 199,229 (616) (174,317) 24,366
Balance, shares at Mar. 31, 2022 [1] 1,672,561        
Balance at Dec. 31, 2021 $ 70 198,772 (171) (168,174) 30,497
Balance, shares at Dec. 31, 2021 [1] 1,672,561        
Net loss         (9,877)
Balance at Jun. 30, 2022 $ 70 199,675 (982) (178,051) 20,712
Balance, shares at Jun. 30, 2022 [1] 1,672,561        
Balance at Mar. 31, 2022 $ 70 199,229 (616) (174,317) 24,366
Balance, shares at Mar. 31, 2022 [1] 1,672,561        
Stock-based compensation 446 446
Unrealized loss from marketable debt securities (366) (366)
Net loss (3,734) (3,734)
Balance at Jun. 30, 2022 $ 70 199,675 (982) (178,051) 20,712
Balance, shares at Jun. 30, 2022 [1] 1,672,561        
Balance at Dec. 31, 2022 $ 70 200,138 (745) (186,040) 13,423
Balance, shares at Dec. 31, 2022 [1] 1,680,232        
Stock-based compensation 297 297
Unrealized loss from marketable debt securities 100 100
Net loss       (1,830) (1,830)
Balance at Mar. 31, 2023 $ 70 200,435 (645) (187,870) 11,990
Balance, shares at Mar. 31, 2023 [1] 1,680,232        
Balance at Dec. 31, 2022 $ 70 200,138 (745) (186,040) 13,423
Balance, shares at Dec. 31, 2022 [1] 1,680,232        
Net loss         (3,423)
Balance at Jun. 30, 2023 $ 70 200,609 (662) (189,463) 10,554
Balance, shares at Jun. 30, 2023 1,680,232        
Balance at Mar. 31, 2023 $ 70 200,435 (645) (187,870) 11,990
Balance, shares at Mar. 31, 2023 [1] 1,680,232        
Stock-based compensation 174 174
Unrealized loss from marketable debt securities (17) (17)
Net loss (1,593) (1,593)
Balance at Jun. 30, 2023 $ 70 $ 200,609 $ (662) $ (189,463) $ 10,554
Balance, shares at Jun. 30, 2023 1,680,232        
[1] Retroactively adjusted (See Note 4.3).
XML 13 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flow from operating activities    
Net loss $ (3,423) $ (9,877)
Adjustments required to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 17 18
Stock-based compensation expense 471 903
Amortization of premium on marketable debt securities 15 35
Change in fair value of SAFE investment (265)
Interest income from short-term deposits (16)
Gain from realization of marketable debt securities (25) 201
Finance expenses (2) (42)
Changes in operating assets and liabilities:    
Decrease in other accounts receivable 484 511
Decrease in trade payables (420) (2,782)
Increase (decrease) in other accounts payable 102 (330)
Net cash used in operating activities (3,062) (11,363)
Cash flow from investing activities    
Purchase of property and equipment (3)
Purchase of available for sale securities (3,218) 10,462
Investment in equity of Onkai (1,500)
Investment in short term deposits (750)
Sale of available-for-sale securities 7,524
Net cash provided by (used in) investing activities 2,056 10,459
Decrease in cash and cash equivalents and restricted cash (1,006) (904)
Cash and cash equivalents and restricted cash at the beginning of the period 2,130 2,998
Cash and cash equivalents and restricted cash at the end of the period 1,124 2,094
Supplemental disclosure of cash flow information:    
Cash received from interest 163 138
Non-cash investment transaction:    
Conversion of SAFE into equity of OnKai $ 1,765
XML 14 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of presentation
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of presentation

Note 1 - Basis of presentation

 

Galmed Pharmaceuticals Ltd. (the “Company”) was incorporated in Israel on July 31, 2013 and commenced operations on February 2, 2014.

 

The Company holds a wholly-owned subsidiary, Galmed International Ltd., which was incorporated in Malta.

 

The Company also holds two additional wholly-owned subsidiaries, Galmed Research and Development Ltd and Galtopa Therapeutics Ltd., both of which are incorporated in Israel.  In July 2023 Galmed Research and Development Ltd established a new wholly-owned subsidiary incorporated under the laws of England and Wales called Galmed Therapeutics  UK limited.

 

The Company is a clinical stage biopharmaceutical company primarily focused on the development of its product candidate Aramchol for liver and fibro-inflammatory diseases. The Company has focused almost exclusively on developing Aramchol for the treatment of NASH and is currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease. The Company is also collaborating with the Hebrew University in the development of Amilo-5MER. The Company has an operating history limited to pre-clinical and clinical drug development.

 

In May 2023, the Company announced the initiation of a new clinical program to evaluate Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC).

 

In addition, in May 2023, the Company entered into a definitive agreement with OnKai, Inc. (“Onkai”) for an equity investment in Onkai. See note 3.

 

The Company funded its research and development programs and operations to date primarily through proceeds from private placements and public offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date. As of June 30, 2023, the Company had cash and cash equivalents of $1.0 million, short term deposit of $0.8 million, restricted cash of $0.1 million, and marketable debt securities of $7.6 million. In July 2023, the Company completed a public offering resulting in net proceeds of approximately $6.2 million.

 

The Company has incurred operating losses in each year since inception. The Company’s loss attributable to holders of its ordinary shares for the six months period ended June 30, 2023, was approximately $3.4 million. As of June 30, 2023, the Company had an accumulated deficit of $189.5 million. Substantially all of its operating losses resulted from costs incurred in connection with the Company’s development program and from general and administrative costs associated with its operations. 

 

The Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol for, and beyond its current development stage and any future commercialization, as well as any additional indications.

 

Based on the Company’s current operating plan, the Company’s management currently estimates that its cash position will support its current clinical trials and operations as currently conducted for more than 12 months from the date of issuance of these financial statements.

 

These unaudited interim condensed consolidated financial statements have been prepared as of June 30, 2023, and for the three and six month period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2022 that are included in the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 29, 2023 (the “Annual Report on Form 20-F”). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2023.

 

 

GALMED PHARMACEUTICALS LTD.

Notes to Interim Condensed Consolidated Financial Statements

 

 
XML 15 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of significant accounting policies
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of significant accounting policies

Note 2 - Summary of significant accounting policies  

 

The significant accounting policies that have been applied in the preparation of the unaudited consolidated interim financial statements are identical to those that were applied in preparation of the Company’s most recent annual financial statements in connection with its Annual Report on Form 20-F, other than:

 

Investment in Equity Securities

 

The Company entered into an investment in which it holds approximately 24% of the outstanding shares and voting rights of Onkai. The Company has elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management believes this approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured at fair value (level 3) at each reporting period through earnings

 
XML 16 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Investment in Associate at Fair Value
 6 Months Ended
Jun. 30, 2023
Investments, All Other Investments [Abstract]  
Investment in Associate at Fair Value

Note 3 – Investment in Associate at Fair Value

 

On May 4, 2023, the Company entered into a definitive agreement (the “Agreement”) for a $1.5 million equity investment in OnKai, a US-based technology company developing an AI-based platform to advance healthcare for underserved populations across the United States by facilitating alignment between healthcare stakeholders.

 

Previously, on November, 2023 the Company invested $1.5 million in OnKai through a Simple Agreement for Future Equity which converted at a 15% discount into series seed preferred shares upon closing of the Investment Round.

 

The Company’s investment in OnKai was part of an approximately $6 million investment round (the “Investment Round”) with other investors that was led by the Company of which SAFE notes of approximately $3.8 million were converted into preferred shares. On June 19, 2023, the Investment Round closed. Following the closing of the Investment Round, the Company holds 1,223,535 preferred shares which comprises approximately 23.9% of the outstanding share capital of OnKai on an as-converted basis. and the Company’s Chief Executive Officer and director, Allen Baharaff serves as a board member of OnKai.  

 

Under the terms of the Agreement, during the three-year period following the closing of the Investment Round the Company will have the right to merge with OnKai subject to the approval of the boards of directors of each of the Company and OnKai. The Company is granted certain customary pre-emptive rights as well as registration rights, first refusal rights, co-sale rights and broad based weighted average anti-dilution rights, a board seat, and certain customary protective provisions.

 

In connection with the Agreement, the Company’s wholly-owned subsidiary, Galmed Research and Development Ltd. (“GRD”), entered into a services agreement with OnKai. The Services Agreement provides that GRD will on a non-exclusive basis (i) provide support services to OnKai relating to finance, business development, strategic planning, execution and others; and (ii) lend its experience to OnKai in building a strategy and for the development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan preparation to serve GRD’s vision of developing drugs for the underserved population and (ii) when relevant, design a process on the clinical trial dashboard that could potentially serve GDR’s future trial.  

 

Summarized statement of operations (in thousands):

 

                     
   Three months ended   Six months ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
                 
Total operating loss  $573  

$

286   $1,171  

$

536 
                     
Net loss  $769   $349   $1,584   $648 

 

 

GALMED PHARMACEUTICALS LTD.

Notes to Interim Condensed Consolidated Financial Statements

 
XML 17 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity
 6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Stockholders’ Equity

Note 4 - Stockholders’ Equity

 

1.On March 23, 2023, the Company received a ruling from the Israel Tax Authority (“ITA”) confirming the repricing of stock options. This repricing was accounted for as a modification of a share-based payment award. The incremental compensation expense recognized as a result of the modification during the period ended June 30, 2023 was approximately $0.1 million.

 

2.On May 15, 2023 the Company effected a reverse share split of the Company’s ordinary shares at the ratio of 1-for-15, such that each fifteen (15) ordinary shares, par value NIS 0.01 per share, shall be consolidated into one (1) ordinary share, par value NIS 0.15. As a result, all share and per share amounts were adjusted retroactively for all periods presented in these financial statements.

 

3.In July 2023, we completed a public offering resulting in net proceeds of approximately $6.2 million. See note 5 for further details.

 
XML 18 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events
 6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 5 – Subsequent Events

 

On July 18, 2023, the Company sold to investors in a public offering (i) 380,000 ordinary shares, (ii) 5,220,000 pre-funded warrants to purchase 5,220,000 ordinary shares (the “Pre-Funded Warrants”), and (iii) 5,600,000 warrants to purchase 5,600,000 ordinary shares (the “Investor Warrants”), at a purchase price of $1.25 per Share and accompanying Investor Warrant and $1.249 per Pre-Funded Warrant and accompanying Investor Warrant.  

 

The Pre-Funded Warrants are immediately exercisable at an exercise price of $0.001 per ordinary share and will not expire until exercised in full. The Investor Warrants have an exercise price of $1.25 per ordinary share, are immediately exercisable, and may be exercised until July 18, 2028. The net proceeds to the Company, were approximately $6.2 million.

 

As of August 4, 2023, a total of 2,121,041 Pre-Funded Warrants were exercised into 2,121,041 ordinary shares.
XML 19 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of significant accounting policies (Policies)
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Investment in Equity Securities

Investment in Equity Securities

 

The Company entered into an investment in which it holds approximately 24% of the outstanding shares and voting rights of Onkai. The Company has elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management believes this approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured at fair value (level 3) at each reporting period through earnings
XML 20 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Investment in Associate at Fair Value (Tables)
 6 Months Ended
Jun. 30, 2023
Investments, All Other Investments [Abstract]  
Summary of Statement of operations

 

                     
   Three months ended   Six months ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
                 
Total operating loss  $573  

$

286   $1,171  

$

536 
                     
Net loss  $769   $349   $1,584   $648 
XML 21 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of presentation (Details Narrative) - USD ($)
$ in Thousands
 1 Months Ended 6 Months Ended
Jul. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]      
Date Of Incorporation   Jul. 31, 2013  
Operations Commenced Date   Feb. 02, 2014  
Cash and cash equivalents   $ 1,009 $ 2,016
Short-term deposits   765
Restricted cash   115 114
Marketable securities debt   7,600  
Proceeds from issuance of initial public offering $ 6,200    
Profit loss   3,400  
Retained earnings accumulated deficit   $ 189,463 $ 186,040
XML 22 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of significant accounting policies (Details Narrative)
Jun. 30, 2023
Onkai Inc [Member]  
Equity Method Investment, Ownership Percentage 24.00%
XML 23 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Statement of operations (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Net loss $ (1,593) $ (1,830) $ (3,734) $ (6,143) $ (3,423) $ (9,877)
Operating Income (Loss) [Member]            
Total operating loss 573   286   1,171 536
Gain (Loss) on Investments [Member]            
Net loss $ 769   $ 349   $ 1,584 $ 648
XML 24 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Investment in Associate at Fair Value (Details Narrative) - USD ($)
$ in Millions
 6 Months Ended
Nov. 30, 2023
Jun. 19, 2023
May 04, 2023
Jun. 30, 2023
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Investment       $ 6.0
Onkai Inc [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Value conversion     $ 1.5 $ 3.8
Stock Issued During Period, Shares, Other   1,223,535    
Converted basis   23.90%    
Onkai Inc [Member] | Subsequent Event [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Value conversion $ 1.5      
Capital stock discount rate 15.00%      
XML 25 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity (Details Narrative) - USD ($)
$ in Millions
 1 Months Ended
Jul. 18, 2023
Jun. 30, 2023
May 15, 2023
Jul. 31, 2023
Subsequent Event [Line Items]        
Other Expenses   $ 0.1    
Stockholders' Equity Note, Stock Split     the Company effected a reverse share split of the Company’s ordinary shares at the ratio of 1-for-15, such that each fifteen (15) ordinary shares, par value NIS 0.01 per share, shall be consolidated into one (1) ordinary share, par value NIS 0.15.  
Proceeds from issuance of initial public offering       $ 6.2
Subsequent Event [Member]        
Subsequent Event [Line Items]        
Proceeds from issuance of initial public offering $ 6.2      
XML 26 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events (Details Narrative) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended
Jul. 18, 2023
Jul. 31, 2023
Aug. 04, 2023
Subsequent Event [Line Items]      
Proceeds from issuance of initial public offering   $ 6.2  
Subsequent Event [Member]      
Subsequent Event [Line Items]      
Number of ordinary shares 380,000    
Proceeds from issuance of initial public offering $ 6.2    
Subsequent Event [Member] | Prefunded Warrants [Member]      
Subsequent Event [Line Items]      
Shares issued price per share $ 1.249    
Shares issued price per share $ 0.001    
Subsequent Event [Member] | Prefunded Warrants [Member] | Warrant [Member]      
Subsequent Event [Line Items]      
Stock and warrants issued during period shares 5,220,000   2,121,041
Subsequent Event [Member] | Prefunded Warrants [Member] | Common Stock [Member]      
Subsequent Event [Line Items]      
Stock and warrants issued during period shares 5,220,000   2,121,041
Subsequent Event [Member] | Investor Warrants [Member]      
Subsequent Event [Line Items]      
Shares issued price per share $ 1.25    
Shares issued price per share $ 1.25    
Subsequent Event [Member] | Investor Warrants [Member] | Warrant [Member]      
Subsequent Event [Line Items]      
Stock and warrants issued during period shares 5,600,000    
Subsequent Event [Member] | Investor Warrants [Member] | Common Stock [Member]      
Subsequent Event [Line Items]      
Stock and warrants issued during period shares 5,600,000    
XML 27 form6-k_htm.xml IDEA: XBRL DOCUMENT 0001595353 2023-01-01 2023-06-30 0001595353 2023-06-30 0001595353 2022-12-31 0001595353 2023-04-01 2023-06-30 0001595353 2022-04-01 2022-06-30 0001595353 2022-01-01 2022-06-30 0001595353 us-gaap:CommonStockMember 2022-12-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001595353 us-gaap:RetainedEarningsMember 2022-12-31 0001595353 us-gaap:CommonStockMember 2023-03-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001595353 us-gaap:RetainedEarningsMember 2023-03-31 0001595353 2023-03-31 0001595353 us-gaap:CommonStockMember 2021-12-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001595353 us-gaap:RetainedEarningsMember 2021-12-31 0001595353 2021-12-31 0001595353 us-gaap:CommonStockMember 2022-03-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001595353 us-gaap:RetainedEarningsMember 2022-03-31 0001595353 2022-03-31 0001595353 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001595353 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001595353 2023-01-01 2023-03-31 0001595353 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001595353 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001595353 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001595353 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001595353 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001595353 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001595353 2022-01-01 2022-03-31 0001595353 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001595353 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001595353 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001595353 us-gaap:CommonStockMember 2023-06-30 0001595353 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001595353 us-gaap:RetainedEarningsMember 2023-06-30 0001595353 us-gaap:CommonStockMember 2022-06-30 0001595353 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001595353 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001595353 us-gaap:RetainedEarningsMember 2022-06-30 0001595353 2022-06-30 0001595353 2023-07-01 2023-07-31 0001595353 GLMD:OnkaiIncMember 2023-06-30 0001595353 GLMD:OnkaiIncMember 2023-05-03 2023-05-04 0001595353 GLMD:OnkaiIncMember us-gaap:SubsequentEventMember 2023-11-29 2023-11-30 0001595353 GLMD:OnkaiIncMember 2023-01-01 2023-06-30 0001595353 GLMD:OnkaiIncMember 2023-06-18 2023-06-19 0001595353 GLMD:OnkaiIncMember 2023-06-19 0001595353 us-gaap:OperatingIncomeLossMember 2023-04-01 2023-06-30 0001595353 us-gaap:OperatingIncomeLossMember 2022-04-01 2022-06-30 0001595353 us-gaap:OperatingIncomeLossMember 2023-01-01 2023-06-30 0001595353 us-gaap:OperatingIncomeLossMember 2022-01-01 2022-06-30 0001595353 us-gaap:GainLossOnInvestmentsMember1 2023-04-01 2023-06-30 0001595353 us-gaap:GainLossOnInvestmentsMember1 2022-04-01 2022-06-30 0001595353 us-gaap:GainLossOnInvestmentsMember1 2023-01-01 2023-06-30 0001595353 us-gaap:GainLossOnInvestmentsMember1 2022-01-01 2022-06-30 0001595353 2023-06-29 2023-06-30 0001595353 2023-05-14 2023-05-15 0001595353 us-gaap:SubsequentEventMember 2023-07-17 2023-07-18 0001595353 us-gaap:WarrantMember us-gaap:SubsequentEventMember GLMD:PrefundedWarrantsMember 2023-07-18 0001595353 us-gaap:CommonStockMember us-gaap:SubsequentEventMember GLMD:PrefundedWarrantsMember 2023-07-18 0001595353 us-gaap:WarrantMember us-gaap:SubsequentEventMember GLMD:InvestorWarrantsMember 2023-07-18 0001595353 us-gaap:CommonStockMember us-gaap:SubsequentEventMember GLMD:InvestorWarrantsMember 2023-07-18 0001595353 us-gaap:SubsequentEventMember GLMD:InvestorWarrantsMember 2023-07-18 0001595353 us-gaap:SubsequentEventMember GLMD:PrefundedWarrantsMember 2023-07-18 0001595353 us-gaap:WarrantMember us-gaap:SubsequentEventMember GLMD:PrefundedWarrantsMember 2023-08-04 0001595353 us-gaap:CommonStockMember us-gaap:SubsequentEventMember GLMD:PrefundedWarrantsMember 2023-08-04 iso4217:USD shares iso4217:USD shares pure iso4217:ILS shares utr:sqft GLMD:Integer iso4217:ILS 0001595353 false --12-31 Q2 2023 2023-06-30 6-K 001-36345 GALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317 IL 1009000 2016000 115000 114000 7556000 11769000 765000 341000 825000 9786000 14724000 129000 223000 97000 114000 1500000 3265000 3491000 1837000 13277000 16561000 2140000 2560000 583000 534000 2723000 3094000 44000 44000 0.15 20000000 1680232 70000 70000 200609000 200138000 -662000 -745000 -189463000 -186040000 10554000 13423000 13277000 16561000 809000 2580000 1892000 7376000 1062000 1150000 1981000 2446000 1871000 3730000 3873000 9822000 278000 -4000 450000 -55000 -1593000 -3734000 -3423000 -9877000 0.95 0.95 2.25 2.25 2.04 2.04 5.85 5.85 1680232 1680232 1672561 1672561 1680232 1680232 1672561 1672561 -1593000 -3734000 -3423000 -9877000 -17000 -366000 83000 -811000 -1610000 -4100000 -3340000 -10688000 1680232 70000 200138000 -745000 -186040000 13423000 297000 297000 100000 100000 -1830000 -1830000 1680232 70000 200435000 -645000 -187870000 11990000 174000 174000 -17000 -17000 -1593000 -1593000 1680232 70000 200609000 -662000 -189463000 10554000 1672561 70000 198772000 -171000 -168174000 30497000 457000 457000 -445000 -445000 -6143000 -6143000 1672561 70000 199229000 -616000 -174317000 24366000 1672561 70000 199229000 -616000 -174317000 24366000 446000 446000 -366000 -366000 -3734000 -3734000 1672561 70000 199675000 -982000 -178051000 20712000 1672561 70000 199675000 -982000 -178051000 20712000 -3423000 -9877000 17000 18000 471000 903000 15000 35000 -265000 16000 25000 -201000 -2000 -42000 -484000 -511000 -420000 -2782000 102000 -330000 -3062000 -11363000 3000 3218000 -10462000 1500000 750000 7524000 2056000 10459000 -1006000 -904000 2130000 2998000 1124000 2094000 163000 138000 1765000 <p id="xdx_80E_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zV9oeuwimbR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Note 1 - <span id="xdx_823_zgyR5MIE93Z3">Basis of presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Galmed Pharmaceuticals Ltd. (the “Company”) was incorporated in Israel on <span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_c20230101__20230630_z13GiZZkBAGk" title="Date Of Incorporation">July 31, 2013</span> and commenced operations on <span id="xdx_90A_eus-gaap--OperationsCommencedDate1_c20230101__20230630_zp9vo0M7FuJa" title="Operations Commenced Date">February 2, 2014</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company holds a wholly-owned subsidiary, Galmed International Ltd., which was incorporated in Malta.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company also holds two additional wholly-owned subsidiaries, Galmed Research and Development Ltd and Galtopa Therapeutics Ltd., both of which are incorporated in Israel.  In July 2023 Galmed Research and Development Ltd established a new wholly-owned subsidiary incorporated under the laws of England and Wales called Galmed Therapeutics  UK limited.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company is a clinical stage biopharmaceutical company primarily focused on the development of its product candidate Aramchol for liver and fibro-inflammatory diseases. The Company has focused almost exclusively on developing Aramchol for the treatment of NASH and is currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease. The Company is also collaborating with the Hebrew University in the development of Amilo-5MER. The Company has an operating history limited to pre-clinical and clinical drug development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In May 2023, the Company announced the initiation of a new clinical program to evaluate Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In addition, in May 2023, the Company entered into a definitive agreement with OnKai, Inc. (“Onkai”) for an equity investment in Onkai. See note 3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company funded its research and development programs and operations to date primarily through proceeds from private placements and public offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date. As of June 30, 2023, the Company had cash and cash equivalents of $<span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20230630_zwQoBHv1Dx21" title="Cash and cash equivalents">1.0</span> million, short term deposit of $<span id="xdx_90D_eus-gaap--DepositsAssetsCurrent_iI_pn5n6_c20230630_zmsCKGe7hMI1" title="Short-term deposits">0.8</span> million, restricted cash of $<span id="xdx_90F_eus-gaap--RestrictedCashCurrent_iI_pn5n6_c20230630_zU8EHhXrwny9" title="Restricted cash">0.1</span> million, and marketable debt securities of $<span id="xdx_906_eus-gaap--ShortTermInvestments_iI_pn5n6_c20230630_zGYMTfvZy61l" title="Marketable securities debt">7.6</span> million. In July 2023, the Company completed a public offering resulting in net proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230701__20230731_zzjztGsKSROj" title="Proceeds from issuance of initial public offering">6.2</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company has incurred operating losses in each year since inception. The Company’s loss attributable to holders of its ordinary shares for the six months period ended June 30, 2023, was approximately $<span id="xdx_90C_eus-gaap--ProfitLoss_pn5n6_c20230101__20230630_zBfxvEGniS1f" title="Profit loss">3.4</span> million. As of June 30, 2023, the Company had an accumulated deficit of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230630_zLyYMMZKW3a1" title="Retained earnings accumulated deficit">189.5</span> million. Substantially all of its operating losses resulted from costs incurred in connection with the Company’s development program and from general and administrative costs associated with its operations. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol for, and beyond its current development stage and any future commercialization, as well as any additional indications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Based on the Company’s current operating plan, the Company’s management currently estimates that its cash position will support its current clinical trials and operations as currently conducted for more than 12 months from the date of issuance of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">These unaudited interim condensed consolidated financial statements have been prepared as of June 30, 2023, and for the three and six month period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2022 that are included in the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 29, 2023 (the “Annual Report on Form 20-F”). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED PHARMACEUTICALS LTD.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Interim Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 2013-07-31 2014-02-02 1000000.0 800000 100000 7600000 6200000 3400000 -189500000 <p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zSarrMDhexm8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - <span><span id="xdx_828_zZOmG99Qfqnc">Summary of significant accounting policies</span></span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant accounting policies that have been applied in the preparation of the unaudited consolidated interim financial statements are identical to those that were applied in preparation of the Company’s most recent annual financial statements in connection with its Annual Report on Form 20-F, other than:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--MarketableSecuritiesPolicy_zxUOtOcksQt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span style="text-decoration: underline"><span id="xdx_86F_zbDtLXBLPKPj">Investment in Equity Securities</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company entered into an investment in which it holds approximately <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OnkaiIncMember_zo7t58lwocP8">24</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">% of the outstanding shares and voting rights of Onkai. The Company has elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management believes this approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured at fair value (level 3) at each reporting period through earnings</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p id="xdx_85B_zUMkbn1mNe34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p id="xdx_841_eus-gaap--MarketableSecuritiesPolicy_zxUOtOcksQt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span style="text-decoration: underline"><span id="xdx_86F_zbDtLXBLPKPj">Investment in Equity Securities</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company entered into an investment in which it holds approximately <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OnkaiIncMember_zo7t58lwocP8">24</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">% of the outstanding shares and voting rights of Onkai. The Company has elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management believes this approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured at fair value (level 3) at each reporting period through earnings</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> 0.24 <p id="xdx_806_eus-gaap--InvestmentTextBlock_zMc5FekzYFqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Note 3 – <span id="xdx_82A_zNNy6RoqK6L5">Investment in Associate at Fair Value</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On May 4, 2023, the Company entered into a definitive agreement (the “Agreement”) for a $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20230503__20230504__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_z9CVmmeumGi7" title="Additional investment on convertible safe notes">1.5</span> million equity investment in OnKai, a US-based technology company developing an AI-based platform to advance healthcare for underserved populations across the United States by facilitating alignment between healthcare stakeholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Previously, on November, 2023 the Company invested $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20231129__20231130__srt--TitleOfIndividualAxis__custom--OnkaiIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zATtJcWwYLfb" title="Additional investment on convertible safe notes">1.5</span> million in OnKai through a Simple Agreement for Future Equity which converted at a <span id="xdx_900_ecustom--CapitalStockDiscountRate_pid_dp_uPure_c20231129__20231130__srt--TitleOfIndividualAxis__custom--OnkaiIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3UW2rD5daQj" title="Capital stock discount rate">15</span>% discount into series seed preferred shares upon closing of the Investment Round.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company’s investment in OnKai was part of an approximately $<span id="xdx_90E_eus-gaap--PaymentsToAcquireInvestments_pn6n6_c20230101__20230630_z5aIfwcw0gC6" title="Investment">6 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">million investment round (the “Investment Round”) with other investors that was led by the Company of which SAFE notes of approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_z7hJPgK2x2kl" title="Value conversion">3.8</span> million </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">were converted into preferred shares. On June 19, 2023, the Investment Round closed. Following the closing of the Investment Round, the Company holds <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230618__20230619__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_z4YJ2ACy2JD9">1,223,535 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">preferred shares which comprises approximately <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230619__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zLf9CiL1m8D9" title="Converted basis">23.9</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">% of the outstanding share capital of OnKai on an as-converted basis. and the Company’s Chief Executive Officer and director, Allen Baharaff serves as a board member of OnKai.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Under the terms of the Agreement, during the three-year period following the closing of the Investment Round the Company will have the right to merge with OnKai subject to the approval of the boards of directors of each of the Company and OnKai. The Company is granted certain customary pre-emptive rights as well as registration rights, first refusal rights, co-sale rights and broad based weighted average anti-dilution rights, a board seat, and certain customary protective provisions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In connection with the Agreement, the Company’s wholly-owned subsidiary, Galmed Research and Development Ltd. (“GRD”), entered into a services agreement with OnKai. The Services Agreement provides that GRD will on a non-exclusive basis (i) provide support services to OnKai relating to finance, business development, strategic planning, execution and others; and (ii) lend its experience to OnKai in building a strategy and for the development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan preparation to serve GRD’s vision of developing drugs for the underserved population and (ii) when relevant, design a process on the clinical trial dashboard that could potentially serve GDR’s future trial.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Summarized statement of operations (in thousands):</b></span></p> <p id="xdx_891_ecustom--SummaryOfStatementOfOperationsTableTextBlock_zf3UmkarI2mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> <span id="xdx_8B0_zzkbIJiq3KFe" style="display: none">Summary of Statement of operations</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td id="xdx_496_20230401__20230630_zKThVrcd9tF2" style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td id="xdx_496_20220401__20220630_zCSiMRgHf8q4" style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td id="xdx_495_20230101__20230630_z9lSIMz7LaAc" style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td id="xdx_495_20220101__20220630_zyuiR5356SX" style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; text-align: center; color: Black"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="6" style="padding: 0pt; color: Black; font-weight: bold; text-align: center">Three months ended</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="6" style="padding: 0pt; color: Black; font-weight: bold; text-align: center">Six months ended</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; text-align: center; color: Black"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding: 0pt; text-align: center; color: Black"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding: 0pt; text-align: center; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; text-align: center; color: Black"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td colspan="2" style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td colspan="2" style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td colspan="2" style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td colspan="2" style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--OperatingIncomeLossMember_zlHBB1xBU2xe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt; width: 44%; color: Black; font-weight: bold; text-align: left">Total operating loss</td><td style="padding: 0pt; width: 2%; color: Black"> </td> <td style="padding: 0pt; width: 1%; color: Black; text-align: left">$</td><td style="padding: 0pt; width: 10%; color: Black; text-align: right">573</td><td style="padding: 0pt; width: 1%; color: Black; text-align: left"> </td><td style="padding: 0pt; width: 2%; color: Black"> </td> <td style="padding: 0pt; width: 1%; color: Black; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">$</p></td><td style="padding: 0pt; width: 10%; color: Black; text-align: right">286</td><td style="padding: 0pt; width: 1%; color: Black; text-align: left"> </td><td style="padding: 0pt; width: 2%; color: Black"> </td> <td style="padding: 0pt; width: 1%; color: Black; text-align: left">$</td><td style="padding: 0pt; width: 10%; color: Black; text-align: right">1,171</td><td style="padding: 0pt; width: 1%; color: Black; text-align: left"> </td><td style="padding: 0pt; width: 2%; color: Black"> </td> <td style="padding: 0pt; width: 1%; color: Black; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">$</p></td><td style="padding: 0pt; width: 10%; color: Black; text-align: right">536</td><td style="padding: 0pt; width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GainLossOnInvestmentsMember1_zycEe0JBXPId" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 2.5pt; color: Black; font-weight: bold; text-align: left">Net loss</td><td style="padding: 0pt 0pt 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: right">769</td><td style="padding: 0pt 0pt 2.5pt; color: Black; text-align: left"> </td><td style="padding: 0pt 0pt 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: right">349</td><td style="padding: 0pt 0pt 2.5pt; color: Black; text-align: left"> </td><td style="padding: 0pt 0pt 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: right">1,584</td><td style="padding: 0pt 0pt 2.5pt; color: Black; text-align: left"> </td><td style="padding: 0pt 0pt 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: right">648</td><td style="padding: 0pt 0pt 2.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zAOGWTdM8bGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>GALMED PHARMACEUTICALS LTD.</b></p> <p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Notes to Interim Condensed Consolidated</b> <b>Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1500000 1500000 0.15 6000000 3800000 1223535 0.239 <p id="xdx_891_ecustom--SummaryOfStatementOfOperationsTableTextBlock_zf3UmkarI2mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> <span id="xdx_8B0_zzkbIJiq3KFe" style="display: none">Summary of Statement of operations</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td id="xdx_496_20230401__20230630_zKThVrcd9tF2" style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td id="xdx_496_20220401__20220630_zCSiMRgHf8q4" style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td id="xdx_495_20230101__20230630_z9lSIMz7LaAc" style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td id="xdx_495_20220101__20220630_zyuiR5356SX" style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; text-align: center; color: Black"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="6" style="padding: 0pt; color: Black; font-weight: bold; text-align: center">Three months ended</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="6" style="padding: 0pt; color: Black; font-weight: bold; text-align: center">Six months ended</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; text-align: center; color: Black"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding: 0pt; text-align: center; color: Black"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding: 0pt; text-align: center; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; text-align: center; color: Black"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; padding: 0pt; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding: 0pt; text-align: center; color: Black; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td colspan="2" style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td colspan="2" style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td colspan="2" style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td colspan="2" style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--OperatingIncomeLossMember_zlHBB1xBU2xe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt; width: 44%; color: Black; font-weight: bold; text-align: left">Total operating loss</td><td style="padding: 0pt; width: 2%; color: Black"> </td> <td style="padding: 0pt; width: 1%; color: Black; text-align: left">$</td><td style="padding: 0pt; width: 10%; color: Black; text-align: right">573</td><td style="padding: 0pt; width: 1%; color: Black; text-align: left"> </td><td style="padding: 0pt; width: 2%; color: Black"> </td> <td style="padding: 0pt; width: 1%; color: Black; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">$</p></td><td style="padding: 0pt; width: 10%; color: Black; text-align: right">286</td><td style="padding: 0pt; width: 1%; color: Black; text-align: left"> </td><td style="padding: 0pt; width: 2%; color: Black"> </td> <td style="padding: 0pt; width: 1%; color: Black; text-align: left">$</td><td style="padding: 0pt; width: 10%; color: Black; text-align: right">1,171</td><td style="padding: 0pt; width: 1%; color: Black; text-align: left"> </td><td style="padding: 0pt; width: 2%; color: Black"> </td> <td style="padding: 0pt; width: 1%; color: Black; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">$</p></td><td style="padding: 0pt; width: 10%; color: Black; text-align: right">536</td><td style="padding: 0pt; width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt; color: Black"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black"> </td> <td style="padding: 0pt; color: Black; text-align: left"> </td><td style="padding: 0pt; color: Black; text-align: right"> </td><td style="padding: 0pt; color: Black; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GainLossOnInvestmentsMember1_zycEe0JBXPId" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 2.5pt; color: Black; font-weight: bold; text-align: left">Net loss</td><td style="padding: 0pt 0pt 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: right">769</td><td style="padding: 0pt 0pt 2.5pt; color: Black; text-align: left"> </td><td style="padding: 0pt 0pt 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: right">349</td><td style="padding: 0pt 0pt 2.5pt; color: Black; text-align: left"> </td><td style="padding: 0pt 0pt 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: right">1,584</td><td style="padding: 0pt 0pt 2.5pt; color: Black; text-align: left"> </td><td style="padding: 0pt 0pt 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; color: Black; text-align: right">648</td><td style="padding: 0pt 0pt 2.5pt; color: Black; text-align: left"> </td></tr> </table> 573000 286000 1171000 536000 769000 349000 1584000 648000 <p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zfIgZeE6Lxid" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Note 4 - <span id="xdx_822_zWpzg1wYkpp4">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On March 23, 2023, the Company received a ruling from the Israel Tax Authority (“ITA”) confirming the repricing of stock options. This repricing was accounted for as a modification of a share-based payment award. The incremental compensation expense recognized as a result of the modification during the period ended June 30, 2023 was approximately $<span id="xdx_902_eus-gaap--OtherExpenses_pn5n6_c20230629__20230630_zTNJM8fs6ikf">0.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">million.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On May 15, 2023 <span id="xdx_90F_eus-gaap--StockholdersEquityNoteStockSplit_c20230514__20230515_zS259eVGmfO1">the Company effected a reverse share split of the Company’s ordinary shares at the ratio of 1-for-15, such that each fifteen (15) ordinary shares, par value NIS 0.01 per share, shall be consolidated into one (1) ordinary share, par value NIS 0.15.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As a result, all share and per share amounts were adjusted retroactively for all periods presented in these financial statements.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In July 2023, we completed a public offering resulting in net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230717__20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHqEGG9C5CQ4" title="Proceeds from issuance of initial public offering">6.2</span> million. See note 5 for further details.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> 100000 the Company effected a reverse share split of the Company’s ordinary shares at the ratio of 1-for-15, such that each fifteen (15) ordinary shares, par value NIS 0.01 per share, shall be consolidated into one (1) ordinary share, par value NIS 0.15. 6200000 <p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zMnbEhpbfNo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Note 5 – <span id="xdx_822_z1THaWcgieUj">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On July 18, 2023, the Company sold to investors in a public offering (i) <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230717__20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWhDKSsLkUkd" title="Number of ordinary shares">380,000</span> ordinary shares, (ii) <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVcTJEVEuDVj" title="Stock and warrants issued during period shares">5,220,000</span> pre-funded warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zisn3rdngCFh" title="Stock and warrants issued during period shares">5,220,000</span> ordinary shares (the “Pre-Funded Warrants”), and (iii) <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_z7hu6IVJHMLe" title="Stock and warrants issued during period shares">5,600,000</span> warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_ziGplWJjmMt4" title="Stock and warrants issued during period shares">5,600,000</span> ordinary shares (the “Investor Warrants”), at a purchase price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zMOu40f6fYoe" title="Shares issued price per share">1.25</span> per Share and accompanying Investor Warrant and $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember_zA0ne6PLV8ea" title="Shares issued price per share">1.249</span> per Pre-Funded Warrant and accompanying Investor Warrant.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Pre-Funded Warrants are immediately exercisable at an exercise price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember_ztFKXTVWno2" title="Share price">0.001</span> per ordinary share and will not expire until exercised in full. The Investor Warrants have an exercise price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_ze8ZFvkBhGb3" title="Shares issued price per share">1.25</span> per ordinary share, are immediately exercisable, and may be exercised until July 18, 2028. The net proceeds to the Company, were approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230717__20230718__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zptQbjFnVvm2" title="Proceeds from issuance of initial public offering">6.2</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As of August 4, 2023, a total of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20230804__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFr3IYbAIfRa" title="Stock and warrants issued during period shares">2,121,041</span> Pre-Funded Warrants were exercised into <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230804__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcZ7hIOSnrG2" title="Stock and warrants issued during period shares">2,121,041</span> ordinary shares.</span></p> 380000 5220000 5220000 5600000 5600000 1.25 1.249 0.001 1.25 6200000 2121041 2121041 Retroactively adjusted (See Note 4.3)   Retroactively adjusted (See Note 4.3)   Retroactively adjusted (See Note 4.3). EXCEL 28 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 29 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 30 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 31 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 78 100 1 true 12 0 false 8 false false R1.htm 00000001 - Document - Cover Sheet http://galmedpharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) Sheet http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets Interim Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Interim Condensed Consolidated Statements of Operations (Unaudited) Sheet http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations Interim Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfComprehensiveLoss Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Changes In Stockholders' Equity (Unaudited) Sheet http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity Consolidated Statements of Changes In Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows Interim Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Basis of presentation Sheet http://galmedpharma.com/role/BasisOfPresentation Basis of presentation Notes 8 false false R9.htm 00000009 - Disclosure - Summary of significant accounting policies Sheet http://galmedpharma.com/role/SummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 9 false false R10.htm 00000010 - Disclosure - Investment in Associate at Fair Value Sheet http://galmedpharma.com/role/InvestmentInAssociateAtFairValue Investment in Associate at Fair Value Notes 10 false false R11.htm 00000011 - Disclosure - Stockholders??? Equity Sheet http://galmedpharma.com/role/StockholdersEquity Stockholders??? Equity Notes 11 false false R12.htm 00000012 - Disclosure - Subsequent Events Sheet http://galmedpharma.com/role/SubsequentEvents Subsequent Events Notes 12 false false R13.htm 00000013 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 13 false false R14.htm 00000014 - Disclosure - Investment in Associate at Fair Value (Tables) Sheet http://galmedpharma.com/role/InvestmentInAssociateAtFairValueTables Investment in Associate at Fair Value (Tables) Tables http://galmedpharma.com/role/InvestmentInAssociateAtFairValue 14 false false R15.htm 00000015 - Disclosure - Basis of presentation (Details Narrative) Sheet http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative Basis of presentation (Details Narrative) Details http://galmedpharma.com/role/BasisOfPresentation 15 false false R16.htm 00000016 - Disclosure - Summary of significant accounting policies (Details Narrative) Sheet http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of significant accounting policies (Details Narrative) Details http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies 16 false false R17.htm 00000017 - Disclosure - Summary of Statement of operations (Details) Sheet http://galmedpharma.com/role/SummaryOfStatementOfOperationsDetails Summary of Statement of operations (Details) Details 17 false false R18.htm 00000018 - Disclosure - Investment in Associate at Fair Value (Details Narrative) Sheet http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative Investment in Associate at Fair Value (Details Narrative) Details http://galmedpharma.com/role/InvestmentInAssociateAtFairValueTables 18 false false R19.htm 00000019 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://galmedpharma.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://galmedpharma.com/role/StockholdersEquity 19 false false R20.htm 00000020 - Disclosure - Subsequent Events (Details Narrative) Sheet http://galmedpharma.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://galmedpharma.com/role/SubsequentEvents 20 false false All Reports Book All Reports form6-k.htm glmd-20230630.xsd glmd-20230630_cal.xml glmd-20230630_def.xml glmd-20230630_lab.xml glmd-20230630_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 33 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form6-k.htm": { "axisCustom": 0, "axisStandard": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 283, "http://xbrl.sec.gov/dei/2023": 14 }, "contextCount": 78, "dts": { "calculationLink": { "local": [ "glmd-20230630_cal.xml" ] }, "definitionLink": { "local": [ "glmd-20230630_def.xml" ] }, "inline": { "local": [ "form6-k.htm" ] }, "labelLink": { "local": [ "glmd-20230630_lab.xml" ] }, "presentationLink": { "local": [ "glmd-20230630_pre.xml" ] }, "schema": { "local": [ "glmd-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 195, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 40, "http://galmedpharma.com/20230630": 2, "http://xbrl.sec.gov/dei/2023": 6, "total": 48 }, "keyCustom": 5, "keyStandard": 95, "memberCustom": 3, "memberStandard": 8, "nsprefix": "GLMD", "nsuri": "http://galmedpharma.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://galmedpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Investment in Associate at Fair Value", "menuCat": "Notes", "order": "10", "role": "http://galmedpharma.com/role/InvestmentInAssociateAtFairValue", "shortName": "Investment in Associate at Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Stockholders\u2019 Equity", "menuCat": "Notes", "order": "11", "role": "http://galmedpharma.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "12", "role": "http://galmedpharma.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Summary of significant accounting policies (Policies)", "menuCat": "Policies", "order": "13", "role": "http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "GLMD:SummaryOfStatementOfOperationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Investment in Associate at Fair Value (Tables)", "menuCat": "Tables", "order": "14", "role": "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueTables", "shortName": "Investment in Associate at Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "GLMD:SummaryOfStatementOfOperationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Basis of presentation (Details Narrative)", "menuCat": "Details", "order": "15", "role": "http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative", "shortName": "Basis of presentation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:MarketableSecuritiesPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "AsOf2023-06-30_custom_OnkaiIncMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Summary of significant accounting policies (Details Narrative)", "menuCat": "Details", "order": "16", "role": "http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of significant accounting policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:MarketableSecuritiesPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "AsOf2023-06-30_custom_OnkaiIncMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Summary of Statement of operations (Details)", "menuCat": "Details", "order": "17", "role": "http://galmedpharma.com/role/SummaryOfStatementOfOperationsDetails", "shortName": "Summary of Statement of operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "GLMD:SummaryOfStatementOfOperationsTableTextBlock", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-04-012023-06-30_us-gaap_OperatingIncomeLossMember", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Investment in Associate at Fair Value (Details Narrative)", "menuCat": "Details", "order": "18", "role": "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative", "shortName": "Investment in Associate at Fair Value (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-06-292023-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "menuCat": "Details", "order": "19", "role": "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-06-292023-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets", "shortName": "Interim Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-07-012023-07-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "20", "role": "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-07-172023-07-18_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "ILSPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "ILSPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Interim Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations", "shortName": "Interim Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfComprehensiveLoss", "shortName": "Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Changes In Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity", "shortName": "Consolidated Statements of Changes In Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember", "decimals": "-3", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows", "shortName": "Interim Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Basis of presentation", "menuCat": "Notes", "order": "8", "role": "http://galmedpharma.com/role/BasisOfPresentation", "shortName": "Basis of presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Summary of significant accounting policies", "menuCat": "Notes", "order": "9", "role": "http://galmedpharma.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 12, "tag": { "GLMD_CapitalStockDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital stock discount rate.", "label": "Capital stock discount rate" } } }, "localname": "CapitalStockDiscountRate", "nsuri": "http://galmedpharma.com/20230630", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative" ], "xbrltype": "percentItemType" }, "GLMD_ChangeInFairValueOfInvestment": { "auth_ref": [], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of investment.", "label": "Change in fair value of SAFE investment" } } }, "localname": "ChangeInFairValueOfInvestment", "nsuri": "http://galmedpharma.com/20230630", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "GLMD_ConversionOfSafeIntoEquityOfOnkai": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of safe into equity of onkai.", "label": "Conversion of SAFE into equity of OnKai" } } }, "localname": "ConversionOfSafeIntoEquityOfOnkai", "nsuri": "http://galmedpharma.com/20230630", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "GLMD_FinanceExpensesAmount": { "auth_ref": [], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance expenses amount.", "label": "Finance expenses" } } }, "localname": "FinanceExpensesAmount", "nsuri": "http://galmedpharma.com/20230630", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "GLMD_InvestorWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investor Warrants [Member]", "label": "Investor Warrants [Member]" } } }, "localname": "InvestorWarrantsMember", "nsuri": "http://galmedpharma.com/20230630", "presentation": [ "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GLMD_OnkaiIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Onkai Inc [Member]", "label": "Onkai Inc [Member]" } } }, "localname": "OnkaiIncMember", "nsuri": "http://galmedpharma.com/20230630", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative", "http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GLMD_PrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prefunded Warrants [Member]", "label": "Prefunded Warrants [Member]" } } }, "localname": "PrefundedWarrantsMember", "nsuri": "http://galmedpharma.com/20230630", "presentation": [ "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GLMD_SummaryOfStatementOfOperationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Statement of Operations [Table Text Block]", "label": "Summary of Statement of operations" } } }, "localname": "SummaryOfStatementOfOperationsTableTextBlock", "nsuri": "http://galmedpharma.com/20230630", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueTables" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r300", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Date Of Incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://galmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [ "r123", "r124", "r125" ], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r123", "r124", "r125" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r326", "r335" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r9", "r277" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Trade payables" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r14", "r15", "r36", "r68", "r201", "r213", "r214" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r1", "r6", "r15", "r170", "r173", "r189", "r209", "r210", "r315", "r316", "r317", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r31", "r277", "r340" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r156", "r157", "r158", "r219", "r323", "r324", "r325", "r333", "r341" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments required to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r4", "r21", "r40", "r141" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of premium on marketable debt securities" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r55", "r67", "r90", "r113", "r116", "r118", "r126", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r163", "r167", "r179", "r199", "r239", "r277", "r288", "r331", "r332", "r336" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r64", "r69", "r90", "r126", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r163", "r167", "r179", "r277", "r331", "r332", "r336" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r90", "r126", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r163", "r167", "r179", "r331", "r332", "r336" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r24", "r47", "r48" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r18", "r66", "r272" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative", "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r18", "r44", "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents and restricted cash at the end of the period", "periodStartLabel": "Cash and cash equivalents and restricted cash at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r0", "r44" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Decrease in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Shares issued price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Stock and warrants issued during period shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Stock and warrants issued during period shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r278", "r279", "r280", "r282", "r283", "r284", "r285", "r323", "r324", "r333", "r339", "r341" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity", "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r30", "r227" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r30", "r227", "r245", "r341", "r342" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r30", "r200", "r277" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Ordinary shares par value NIS 0.15 per share; Authorized 20,000,000; Issued and outstanding: 1,680,232 shares as of June 30, 2023 and as of December 31, 2022 ()" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r20", "r54", "r73", "r75", "r79", "r194", "r207" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "negatedTotalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r12", "r140" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Converted basis" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "auth_ref": [ "r328", "r329" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "negatedLabel": "Net unrealized loss (gain) on available for sale securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r314" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Short term Deposits", "verboseLabel": "Short-term deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative", "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r4", "r114" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r80", "r96", "r97", "r98", "r99", "r100", "r104", "r106", "r108", "r109", "r110", "r111", "r177", "r178", "r195", "r208", "r273" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r80", "r96", "r97", "r98", "r99", "r100", "r106", "r108", "r109", "r110", "r111", "r177", "r178", "r195", "r208", "r273" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r7", "r62", "r76", "r77", "r78", "r91", "r92", "r93", "r95", "r101", "r103", "r112", "r127", "r128", "r155", "r156", "r157", "r158", "r160", "r161", "r169", "r170", "r171", "r172", "r173", "r174", "r176", "r180", "r181", "r182", "r183", "r184", "r185", "r189", "r209", "r210", "r211", "r219", "r265" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity", "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_GainLossOnInvestmentsMember1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing gain (loss) on investments.", "label": "Gain (Loss) on Investments [Member]" } } }, "localname": "GainLossOnInvestmentsMember1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SummaryOfStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r38", "r249" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r129", "r130", "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SummaryOfStatementOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r130", "r250" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SummaryOfStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r3" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Decrease in other accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r3" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Decrease in trade payables" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayable": { "auth_ref": [ "r3" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Increase (decrease) in other accounts payable" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeShortTermInvestmentOther": { "auth_ref": [ "r60", "r61" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income from short-term investment classified as other.", "label": "Interest Income, Short-Term Investment, Other", "negatedLabel": "Interest income from short-term deposits" } } }, "localname": "InterestIncomeShortTermInvestmentOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r82", "r85", "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash received from interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r309", "r310", "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment in Associate at Fair Value" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r198" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investment in SAFE notes" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r312" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investment in associate at fair value" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r35", "r56", "r203", "r277", "r322", "r330", "r334" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r11", "r65", "r90", "r126", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r164", "r167", "r168", "r179", "r277", "r331", "r336", "r337" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r8", "r25", "r26", "r27", "r28", "r90", "r126", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r164", "r167", "r168", "r179", "r331", "r336", "r337" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r313" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable debt securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Gain (Loss)", "negatedLabel": "Gain from realization of marketable debt securities" } } }, "localname": "MarketableSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Investment in Equity Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flow from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r44", "r45", "r46" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flow from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r37", "r46", "r59", "r63", "r72", "r74", "r78", "r90", "r94", "r96", "r97", "r98", "r99", "r102", "r103", "r107", "r113", "r115", "r117", "r119", "r126", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r178", "r179", "r206", "r247", "r263", "r264", "r274", "r286", "r331" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "negatedLabel": "Net loss", "negatedTotalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows", "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfComprehensiveLoss", "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations", "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity", "http://galmedpharma.com/role/SummaryOfStatementOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investment transaction:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r113", "r115", "r117", "r119", "r274" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Total operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SummaryOfStatementOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing operating income (loss).", "label": "Operating Income (Loss) [Member]" } } }, "localname": "OperatingIncomeLossMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SummaryOfStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r188" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r187" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperationsCommencedDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the operations of the entity commenced, in YYYY-MM-DD format.", "label": "Operations Commenced Date" } } }, "localname": "OperationsCommencedDate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r70", "r71", "r122" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized loss from marketable debt securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLoansPayableCurrent": { "auth_ref": [ "r10", "r225", "r226" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term loans classified as other, payable within one year or the operating cycle, if longer.", "label": "Other payables" } } }, "localname": "OtherLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r41" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Financial expense (income), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm": { "auth_ref": [ "r318", "r319", "r320" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow (inflow) through acquisition (sale) of short-term available-for-sale securities.", "label": "Payments for (Proceeds from) Available-for-Sale Securities, Short-Term", "negatedLabel": "Purchase of available for sale securities" } } }, "localname": "PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromShortTermInvestments": { "auth_ref": [ "r318", "r319", "r320" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments for (Proceeds from) Short-Term Investments", "negatedLabel": "Investment in short term deposits" } } }, "localname": "PaymentsForProceedsFromShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r17" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedLabel": "Investment in equity of Onkai" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Investment" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r43" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r2" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from issuance of initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative", "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative", "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r16", "r81", "r120", "r121" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Sale of available-for-sale securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r63", "r72", "r74", "r83", "r90", "r94", "r102", "r103", "r113", "r115", "r117", "r119", "r126", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r162", "r165", "r166", "r178", "r179", "r196", "r205", "r218", "r247", "r263", "r264", "r274", "r275", "r276", "r287", "r317", "r331" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r5", "r197", "r204", "r277" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r23", "r159", "r338" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r311", "r321" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative", "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r32", "r51", "r202", "r212", "r214", "r217", "r228", "r277" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Retained earnings accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative", "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r62", "r91", "r92", "r93", "r95", "r101", "r103", "r127", "r128", "r156", "r157", "r158", "r160", "r161", "r169", "r171", "r172", "r174", "r176", "r209", "r211", "r219", "r341" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r19", "r53" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Shares issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r57", "r58", "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Marketable securities debt" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r47", "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r7", "r13", "r62", "r76", "r77", "r78", "r91", "r92", "r93", "r95", "r101", "r103", "r112", "r127", "r128", "r155", "r156", "r157", "r158", "r160", "r161", "r169", "r170", "r171", "r172", "r173", "r174", "r176", "r180", "r181", "r182", "r183", "r184", "r185", "r189", "r209", "r210", "r211", "r219", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity", "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r91", "r92", "r93", "r112", "r193", "r215", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r246", "r248", "r249", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r265", "r281" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity", "http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://galmedpharma.com/role/SummaryOfStatementOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r91", "r92", "r93", "r112", "r193", "r215", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r246", "r248", "r249", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r265", "r281" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity", "http://galmedpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://galmedpharma.com/role/SummaryOfStatementOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r7", "r29", "r30", "r51", "r216", "r265", "r270" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of ordinary shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r7", "r13", "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Value conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r30", "r33", "r34", "r49", "r229", "r245", "r266", "r267", "r277", "r288", "r322", "r330", "r334", "r341" ], "calculation": { "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedBalanceSheets", "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r50", "r89", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r155", "r175", "r268", "r269", "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplit": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.", "label": "Stockholders' Equity Note, Stock Split" } } }, "localname": "StockholdersEquityNoteStockSplit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r186", "r191" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative", "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r186", "r191" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative", "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative", "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r186", "r191" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative", "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r186", "r191" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative", "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative", "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r186", "r191" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InvestmentInAssociateAtFairValueDetailsNarrative", "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative", "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r190", "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r278", "r279", "r282", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r105", "r110" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average number of shares outstanding used in computing net loss per share, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r104", "r110" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares outstanding used in computing net loss per share, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://galmedpharma.com/role/InterimCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r289": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r291": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r292": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r293": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r294": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r295": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r296": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r297": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r298": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r299": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r301": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r302": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r303": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r304": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r305": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r306": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r307": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r308": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "https://asc.fasb.org//321/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "https://asc.fasb.org//325/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 34 0001493152-23-027375-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-027375-xbrl.zip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end